Evidence map›Paper›PMID 42564720›Full record

ArticleMolecular therapy. Advances2026

Safety and HBsAg reduction with a lentiviral vaccine J-51 in chronic hepatitis B: An investigator-initiated pilot trial.

Jieyu Song, Qiran Zhang, Yumeng Zhang, Jingjing Shen, Rongrong Wei, Kun Wang, Chunyan Shen, Wenjuan Wang, Mingmei Chu, Fang Zhou and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jieyu SongDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China.
Qiran ZhangDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China.
Yumeng ZhangDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China.
Jingjing ShenChangzhi People's Hospital, Changzhi 046000, China.
Rongrong WeiChangzhi People's Hospital, Changzhi 046000, China.
Kun WangChangzhi People's Hospital, Changzhi 046000, China.
Chunyan ShenChangzhi People's Hospital, Changzhi 046000, China.
Wenjuan WangChangzhi People's Hospital, Changzhi 046000, China.
Mingmei ChuJinwei Biotechnology, Shanghai 201318, China.
Fang ZhouJinwei Biotechnology, Shanghai 201318, China.
Xiao LiangJinwei Biotechnology, Shanghai 201318, China.
Linshu ZhangJinwei Biotechnology, Shanghai 201318, China.
Jingyan HuangJinwei Biotechnology, Shanghai 201318, China.
Chao QiuDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China.
Hong WuChangzhi People's Hospital, Changzhi 046000, China.
Wenhong ZhangDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This first-in-human, investigator-initiated trial evaluated the novel non-integrating lentiviral-vector-based therapeutic vaccine J-51 for chronic hepatitis B. The open-label pilot study enrolled seven HBeAg-negative patients with HBsAg <5,000 IU/mL. Participants received varying doses (5.0 × 10

Indexed as

chronic hepatitis Bfirst-in-human trialimmunotherapylentiviral vectortherapeutic vaccine

Identifiers

PMID42564720
PMCPMC13444524

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.